Valeant Pharmaceuticals International (VRX) : The total negative money flow of $29.49 million on Thursday indicates selling on strength. The inflow of money on upticks was $287.6 million, compared to $317.08 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.91. The negative money flow of $6.22 million in block trades reveals that the informed traders sold the stock on every bit of price strength. The traded value of the stock on uptick was $19.84 million in a block trade.The transaction value of block trade on downtick was $26.06 million. The uptick to downtick ratio was 0.76. The price action in the Valeant Pharmaceuticals International (VRX) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $23.02 with a gain of $1.4 , a change of 6.48% over the previous days close. The stock registered -0.99% for the week.
The stock has recorded a 20-day Moving Average of 6.16% and the 50-Day Moving Average is 9.07%. Shares have dropped -90.18% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $263.81 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $23.97 and the 200 Day Moving Average price is recorded at $51.31.
Valeant Pharmaceuticals International (NYSE:VRX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $21.91 and $21.45 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $23.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.02, notching a gain of 6.48% for the day. The total traded volume was 49,842,743 . The stock had closed at $21.62 on the previous day.
In an insider trading activity, Ross Thomas W. Sr., Director of Valeant Pharmaceuticals International, Inc., had purchased 4,000 shares on June 13, 2016. The total value of the transaction was $97,600. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.